Keyphrases
Radioimmunotherapy
100%
Indolent Lymphoma
100%
Low-grade Lymphoma
100%
Treatment Strategy
66%
Randomized Phase III Trial
66%
Monoclonal Antibody
33%
New Drug Targets
33%
Overall Survival
33%
Patient Management
33%
Clinical Outcomes
33%
Patient's Will
33%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
33%
New Treatment Options
33%
Lymphoma
33%
Progression-free Survival
33%
Recent Advances
33%
Therapeutic Vaccination
33%
Long-term Clinical Outcome
33%
Antibody Targeting
33%
Optimal Treatment
33%
Rituximab
33%
Lymphoma Therapy
33%
Chemotherapy Alone
33%
Combination Chemotherapy
33%
Indolent non-Hodgkin Lymphoma
33%
Long-term Toxicity
33%
Modern Treatment
33%
Associated Antigen
33%
Medicine and Dentistry
Non-Hodgkin Lymphoma
100%
Radioimmunotherapy
100%
Immunotherapy
100%
Phase III Trials
100%
Overall Survival
50%
Progression Free Survival
50%
Patient Care
50%
Rituximab
50%
Combination Chemotherapy
50%
Allogeneic Hematopoietic Stem Cell Transplantation
50%
Monoclonal Antibody
50%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Nonhodgkin Lymphoma
100%
Immunotherapy
100%
Phase III Trials
100%
Overall Survival
50%
Progression Free Survival
50%
Rituximab
50%
Monoclonal Antibody
50%